Influence of estrogen in non-small cell lung cancer and its clinical implications

• Published in: Journal of thoracic disease Vol. 10; no. 1; pp. 482 - 497
• Main Authors: Rodriguez-Lara, Vianey, Hernandez-Martinez, Juan-Manuel, Arrieta, Oscar
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01-01-2018
• Subjects: Review; estrogen; estrogen receptor; antiestrogen therapy; Non-small cell lung cancer (NSCLC)
• ISSN: 2072-1439; 2077-6624
• DOI: 10.21037/jtd.2017.12.61

Lung cancer (LC) is the leading cause of cancer death in men worldwide and has significantly increased in women. Differences in non-small cell lung cancer (NSCLC) behavior, prognosis, and response to treatment have been reported by sex and hormonal status, with premenopausal women presenting the worst prognosis compared to postmenopausal women and men. Additionally, the use of hormonal replacement therapy significantly increases NSCLC mortality; supporting the role of estrogen signaling in the pathogenesis of LC. The mechanisms by which estrogen promotes lung carcinogenesis have not been fully elucidated. Estrogen, through its receptor, can stimulate LC cell proliferation, death resistance, angiogenesis, migration and metastasis. Estrogen also induces expression of pro-inflammatory proteins and ligands that promote tumor evasion, suggesting that estrogen might modify the microenvironment and anti-tumor immune response. Recent reports have shown an interaction between the epidermal growth factor receptor (EGFR) pathway and estrogen signaling in lung adenocarcinoma, whence, combined treatment based on tyrosine kinase inhibitors (TKIs) and antiestrogen therapy is beginning to be evaluated. This review focuses on the differences in NSCLC behavior by sex and hormonal status, highlighting the role of estrogen and its receptors in lung carcinogenesis and LC prognosis. Due to the importance of estrogen in NSCLC development and progression we finally discuss the potential of antiestrogen therapy in LC treatment and show the results from preclinical and clinical trials.